Build a credible path
into the US healthcare market.

US commercialisation strategy for UK and European medtech and digital health companies.

Ionea helps healthcare companies build the commercial logic, go-to-market model and early market-access pathway required to approach the US with clarity.

Discuss your US strategy Explore our services→

01Why Ionea

The US is not simply a larger version of your home market.

The customer, buyer, payment model, evidence expectations, regulatory pathway and route to adoption may all be different.

Entering without a clear commercial strategy can lead to costly delays, misplaced investment and conversations with the wrong stakeholders.

Ionea helps leadership teams translate a promising healthcare product into a coherent, evidence-based US market strategy.

02What we do

Commercial strategy built around the realities of US healthcare.

US Go-to-Market Strategy

Define the customers, buyers, users and commercial model most relevant to the US opportunity.

Ionea helps companies identify where their product creates value in the US healthcare system, who is most likely to buy it and how the commercial proposition should be structured.

Customer and buyer identification
Use-case and market-segment prioritisation
Value proposition and positioning
Pricing and commercial-model development
Direct, partnership, distribution or licensing routes
Initial launch and market-entry roadmap

US Commercial Business Case

Build the evidence-based case for pursuing the US market and provide leadership teams with a clear basis for investment and decision-making.

The business case brings together market, commercial and strategic evidence to help companies decide how to approach the opportunity and what investment will be required.

Market and opportunity analysis
Competitive positioning
Customer and use-case prioritisation
Revenue and pricing assumptions
Adoption and sales-cycle assumptions
Commercial costs and resource requirements
Risks, dependencies and evidence gaps
Leadership, board or investor-ready recommendations

Coding, Payment and FDA Pathway Scoping

Explore how coding, payment and regulatory considerations may shape the commercial pathway before formal specialist execution begins.

Ionea helps companies understand the wider strategic landscape and incorporate early market-access and regulatory considerations into the commercial plan.

Ionea provides strategic research and pathway scoping. It does not prepare or submit regulatory documentation and does not provide formal legal, regulatory or reimbursement advice.

Existing coding landscape research
Payment and reimbursement pathway research
FDA product classification research
Potential regulatory pathway considerations
Predicate-device landscape research
Strategic questions for regulatory and reimbursement specialists
Identification of areas requiring formal specialist support

Fractional Commercial Strategy

Work alongside the leadership team as the company develops and begins implementing its US commercial strategy.

Ongoing strategic leadership
Founder and leadership-team support
Commercial priority setting
Partner and stakeholder prioritisation
Commercial narrative and materials
Coordination with specialist advisers
Preparation for early US market engagement

Healthcare professional using a digital health platform on a tablet.

Commercial strategy must connect the product, the healthcare system and the path to adoption.

03Our approach

Rigorous thinking. Practical direction.

Define the question

Clarify the product, intended use, commercial objectives and strategic decisions the company needs to make.

Build the evidence base

Research the market, customer, competitive, coding, payment and regulatory landscape relevant to the opportunity.

Shape the strategy

Translate the evidence into clear decisions around customer, positioning, business model and pathway.

Create the roadmap

Turn the strategy into sequenced priorities, resource requirements and practical next steps.

04Who we work with

For UK and European healthcare companies preparing to take the US seriously.

Ionea works primarily with UK and European medtech and digital health companies that have developed a functioning product, established initial evidence or market traction, and are considering US expansion within the next 6–18 months.

The work is particularly suited to companies navigating:

Complex healthcare buying pathways
Regulated medical products
Coding or payment questions
Multiple potential customers or commercial models
The need to build a credible internal or investor business case
A transition from UK or European traction to a US commercial strategy

Dr Ioanna Syntouka — Founder

05About Ionea

Commercial strategy grounded in healthcare, technology and execution.

Ionea was founded by Dr Ioanna Syntouka, a biomedical engineer and healthcare operator with experience across medical devices, digital health, product development, clinical programmes, business development and startup operations.

Having worked with healthcare companies across the UK, Europe and the US, Ioanna brings together technical understanding, clinical context and commercial thinking.

Her work focuses on helping leadership teams make clearer decisions, build stronger business cases and develop credible routes into the US healthcare market.

Considering the US market?

Whether you are developing the initial business case or refining an existing market-entry plan, start with a conversation about the questions that matter most.

Start a conversation

Build a credible path into the US healthcare market.